WSC
GBT

White Square Capital’s Global Blood Therapeutics, Inc. GBT Stock Holding History

White Square Capital’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,454,365
Closed -$53.6M – 5
2017
Q1 		$53.6M Buy
+1,454,365
New +$36.6M 22.56% 1

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

White Square Capital's GBT Position: Q2 2017 in Review

White Square Capital sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2017, closing a stake of 1,454,365 shares — an estimated $53.6M sold.

White Square Capital first reported a position in GBT in Q1 2017 and held it in 1 quarter. The position peaked at $53.6M in Q1 2017. 134 funds tracked by Wall St. Rank hold GBT as of Q2 2017.

  • White Square Capital reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • White Square Capital sold 1,454,365 Global Blood Therapeutics, Inc. shares in Q2 2017, an estimated $53.6M.
  • White Square Capital first reported a position in Global Blood Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • White Square Capital's Global Blood Therapeutics, Inc. position peaked at $53.6M in Q1 2017.
  • 134 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2017.

Based on White Square Capital's 13F filing for Q2 2017, filed 11 Aug 2017.